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The modern era of angiogenesis research is generally con-
sidered to have begun with the proposal by Folkman
(1971) that tumors release diffusible factors that promote
the formation of new blood vessels. Although there has
been interest in this topic for 30 yr, the last 6–7 yr have
seen an explosion of interest in this field. This explosion is
evidenced in the number of meetings on the topic, the
number of press reports, and especially the number of
publications. A search of the Medline database reveals
that in 1990 approximately 200 papers were published on
the topic of angiogenesis, whereas in the year 2000 more
than 1,700 papers appeared on the same subject. To what
can we attribute this rise? My own feeling is that while the
previous two decades were devoted to proving that angio-
genesis was a real biological phenomenon and to the isola-
tion of angiogenesis-stimulating factors, the 1990s were
devoted to the identification, purification, and cloning of
potentially effective angiogenesis inhibitors. This allowed
the establishment of clinical trials to test the therapeutic
efficacy of these agents and has stimulated a torrent of ac-
tivity among biologists in both academic and industrial set-
tings to find out more about the mechanisms by which
these inhibitors work.
 
A large number of angiogenesis inhibitors have entered
or will soon enter clinical trials. These have been identi-
fied and isolated using a variety of strategies. Some were
chosen on the basis of their ability to interfere with key
angiogenesis stimulators such as the vascular endothelial
growth factor and its receptors (Presta et al., 1997; Fong et
al., 1999) or key endothelial receptors for extracellular
 
matrix molecules such as the 
 
a
 
v
 
b
 
3 integrin (Brooks et al.,
1994). Others were isolated from tissues such as cartilage
that are naturally devoid of blood vessels (Moses et al.,
 
1999). Some were known cytokines such as interferon alpha
(White et al., 1989) or interleukin 12 (Voest et al., 1995)
that were subsequently found to have antiangiogenic prop-
erties. Still others were identified on the basis of their struc-
tural characteristics (D’Amato et al., 1994; Klauber et al.,
 
1997) or on the basis of their ability to inhibit endothelial
cell migration or proliferation (Ingber et al., 1990) or to func-
tion as a tumor suppressor (Good et al., 1990). Information
regarding angiogenesis inhibitors in clinical trials can be
 
found on the Cancer Trials web site of the National Can-
cer Institute (http://cancertrials.nci.nih.gov/news/angio/
table.html).
One of the first angiogenesis inhibitors described in the
1990s was angiostatin, a molecule originally collected from
the urine of tumor-bearing mice (O’Reilly et al., 1994).
Angiostatin is a proteolytically generated fragment of
plasminogen consisting of the first four kringle domains of
the parent molecule. Angiostatin is thought not to be pro-
duced inside the tumor cells, but rather to be generated in
the circulation by tumor-derived proteolytic enzymes
(Gately et al., 1996). The observation that angiostatin as
well as other angiogenic inhibitors are derived from mole-
cules involved in hemostasis has encouraged speculation
that these molecules may have a role in normal wound
healing, as well as in tumors and other pathological states
(Browder et al., 2000). Angiostatin is currently in clinical
trials to determine its utility as an antitumor drug.
 
Despite the intense effort and research output on the
topic of angiogenesis inhibitors, much remains to be
learned. For many of these newly described inhibitors, we
know little of their mechanism of action and less about the
nature of the receptors that mediate their effects on en-
dothelial cells. For this reason, the paper by Troyanovsky
et al. (2001) is a welcome addition to our understanding of
angiogenesis. This team has described angiomotin, a new,
functional angiostatin-binding protein that mediates the
inhibition of endothelial cell motility, a critical component
of the angiogenic process (Zetter, 1980). Because of the
importance of cell migration in the angiogenesis process,
the discovery of a cell-surface protein that mediates the ef-
fects of angiostatin on endothelial cell motility represents
a significant step forward for this field.
The data are convincing. Angiomotin was discovered us-
ing a yeast two-hybrid screen for proteins that interact
with the first four kringle domains of plasminogen. It is de-
scribed as a 72-kD cell surface–associated protein that is
expressed in capillary endothelial cells as well as in ac-
tively angiogenic tissue such as placenta and solid tumors.
Like other surface-associated proteins that can bind plas-
minogen and its derivatives, angiomotin does not appear
to have a signal sequence, thus its association with the cell
surface may be via protein–protein interaction. It is local-
ized to the lamellipodia at the leading edge of migrating
endothelial cells. Most importantly, transfection of control
HeLa cells with angiomotin results in an increased re-
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sponse to migration-stimulating proteins. Furthermore,
angiostatin treatment blocked cell migration and three-
dimensional tube morphogenesis in cells transfected with
angiomotin but not in vector-control cells. These results
solidly implicate angiomotin in the angiostatin-mediated
regulation of cell motility and capillary differentiation.
Angiomotin is not the first angiostatin-binding protein
discovered. ATP synthase was previously described as a
high affinity angiostatin-binding protein (Moser et al., 1999)
that bound preferentially to angiostatin relative to the par-
ent molecule plasminogen. Antibodies to ATP synthase
were reported to inhibit the antiproliferative activity of an-
giostatin on endothelial cells. Plasminogen itself binds to
other cell-surface proteins such as annexin II and alpha eno-
lase (Miles et al., 1991; Hajjar et al., 1994). Should we be
concerned, then, that a potent antiangiogenic molecule
should have more than one potentially important cell sur-
face binding molecule? Probably not. The positive and
negative regulation of blood vessel growth is a critical deter-
minant of tissue repair and of normal tissue mass. Angio-
genesis has essential roles in embryonic development, tissue
hyperplasia, and a variety of diseases. Vascular endothelial
growth factor (VEGF), a positive regulator of angiogenesis,
has at least three receptors, and fibroblast growth factor,
another positive regulator, has more receptors than VEGF.
It would be no surprise if a potent angiogenesis inhibitor
such as angiostatin were to have multiple receptors. These
multiple receptors could act independently or in concert, as
is the case for the high- and low-affinity receptors for fibro-
blast growth factor (Yayon et al., 1991).
As always, a discovery of this type generates many new
questions. Among those undoubtedly being asked in the
Holmgren laboratory today are: (a) what is the binding af-
finity of angiostatin’s interaction with angiomotin? (b)
what is the nature of the binding interactions between an-
giomotin and plasminogen? (c) what signaling molecules
are downstream of angiomotin? (d) does binding of an-
giostatin to angiomotin cause activation of the focal adhe-
sion kinase previously shown to be modulated by angiosta-
tin (Claesson-Welsh et al., 1998)? and (e) does angiomotin
mediate other functions of angiostatin action such as en-
dothelial proliferation in vitro or the inhibition of angio-
genesis and tumor growth in vivo? There is considerable
work left to be done.
Who are the beneficiaries of this new discovery? Those
who will try to add more flesh to the bones of this new
finding, those who will attempt to identify or construct
novel small molecules that regulate angiogenesis via the
angiomotin pathway, those curious about angiogenesis,
and, with any luck, those who may have or will later ac-
quire a disease characterized by untoward angiogenesis.
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